Giants of Cancer Care® Program Inductees

Genitourinary Cancer

Howard I. Scher, MD

Memorial Sloan Kettering Cancer Center

Scher is cochair of the Center for Mechanism Based Therapy, head of the Biomarker Development Initiative, and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He is also a professor of medicine at Weill Cornell Medical College.
Throughout his milestone career, Scher has had a research focus to define key molecular and genetic features of prostate cancer.
He led the Prostate Cancer Clinical Trials Working Group 3 in an international effort to develop standards for the design, conduct, and analysis of phase 2 prostate cancer trials.
In 2011, Scher and coauthors published findings from the NCT00638690 trial that demonstrated that abiraterone acetate (Zytiga) improved survival outcomes vs placebo in patients with prolonged overall survival among patients with metastatic castration-resistant prostate cancer, but also was the first to report findings from supersensitive assays involving mass spectroscopy levels that helped to redefine the concept of castrate-range testosterone levels.
Scher also developed the Clinical States Model of Prostate Cancer Progression, which offers a framework for assessing prognosis and guiding management as a cancer evolves over time.
He is the primary investigator for the Memorial Sloan Kettering Prostate Cancer Specialized Program of Research Excellence, which uses a biomarker-based and risk-adapted approach to improve the understanding of the prostate tumor growth drivers.

Home

)

SUPPORTED BY